Home / Disease / Halozyme reports pancreatic cancer trial success stat : sandiegouniontribune
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

Halozyme reports pancreatic cancer trial success stat : sandiegouniontribune

This content may collect you by Alice Julian

We will quote to you most important and trendy news about Cancer of the best health sites Like : “sandiegouniontribune” and the most famous medical experts : Bradley J. Fikes

daily : 2017-01-05 & on time : 16:35

according to

Halozyme reports pancreatic cancer trial success

Halozyme reports pancreatic cancer trial success

image uploaded by “sandiegouniontribune” site

San Diego’s Halozyme Therapeutics reported positive clinical results for the use of its drug PEGPH20 in combination therapy for pancreatic cancer.Among the results, a Phase 2 trial found a statistically significant increase in survival without progression of patients with Stage IV pancreatic cancer.These patients experienced a median 8.6 months in progression-free survival compared to 4.5 months among control patients.

about the details read more from here

Halozyme’s pancreatic cancer drug succeeds in mid-stage trial

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

image uploaded by “reuters” site

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.Halozyme’s PEGPH20, in combination with Celgene’s Abraxane and Lilly’s gemcitabine, provided a statistically significant benefit in helping patients with high levels of hyaluronan (HA) live longer without their cancer worsening.PEGPH20 is an enzyme that targets and degrades HA, a chain of natural sugars found on human tissue that can accumulate in higher concentrations around certain cancer cells and potentially constrict blood vessels and impede other therapies.

about the details read more from here

Halozyme jumps, then lands, on positive late-stage pancreatic cancer data

Halozyme jumps, then lands, on positive late-stage pancreatic cancer data

image uploaded by “fiercebiotech” site

Halozyme saw its shares boosted by nearly 60% premarket on news that it had hit its endpoints in a midstage test of its candidate in the notoriously difficult-to-treat pancreatic cancer therapy area, but its shares rally did not last long.In the phase 2 trial posted this morning, the San Diego biotech showed a statistically significant improvement in progression-free survival (PFS) in all evaluable patients, as well as in patients with high levels of hyaluronan, in what could also be a potential new biomarker in the disease.The biotech also hit its endpoint of reducing thromboembolic events, although all of these data are only from a subset of patients, and the actual details were thin on the ground.

about the details read more from here

To follow all the new news about Cancer

Check Also

picture.jpg

fatness average within adults are at an all-time high in Georgia

fatness average within adults are at an all-time high in Georgia. “fatness is an epidemic, …